2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
- Generic Name
- 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C39H48N4O4
- CAS Number
- 149402-51-7
- Unique Ingredient Identifier
- DOB7Y3RSX0
- Background
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03090412
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Rocherster, Rochester, New York, United States
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Stage I Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage I Verrucous Carcinoma of the Oral CavityStage II Verrucous Carcinoma of the Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavityStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage III Verrucous Carcinoma of the Oral CavityStage IVA Verrucous Carcinoma of the Oral CavityStage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02119728
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy in Treating Patients With Lung Cancer
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT01668823
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01238042
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01236443
- Locations
- 🇺🇸
Roswell Park cancer institute, Buffalo, New York, United States
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
- Conditions
- Interventions
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT01140178
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00675233
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00670397
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00528775
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00526461
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.